Cited 103 times in
Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김자경 | - |
dc.contributor.author | 박민찬 | - |
dc.contributor.author | 박용범 | - |
dc.contributor.author | 이수곤 | - |
dc.date.accessioned | 2015-04-24T17:25:12Z | - |
dc.date.available | 2015-04-24T17:25:12Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0315-162X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/105365 | - |
dc.description.abstract | OBJECTIVE: To investigate whether anti-tumor necrosis factor-alpha (TNF-alpha) therapy can influence the reactivation of hepatitis B virus (HBV) infection in inactive HBsAg carriers. METHODS: The medical records of 103 patients [59 with ankylosing spondylitis (AS), 41 with rheumatoid arthritis (RA), 2 with juvenile RA, and 1 with psoriatic arthritis] who had been treated with anti-TNF-alpha therapy were reviewed retrospectively. Data on seropositivity of HBV, HBV load, and serum aminotransferases prior to and after initiation of anti-TNF-alpha therapy were obtained. RESULTS: Eight patients were inactive HBsAg carriers, and all of them had normal liver function and undetectable HBV load prior to anti-TNF-alpha therapy. Reactivation of hepatitis B occurred in 1 patient during the course of anti-TNF-alpha therapy. After the third infusion of infliximab 5 mg/kg at Week 6, a blood test showed that the patient had normal liver function. When the patient returned for the fourth infusion of infliximab at Week 14, a blood test showed markedly elevated aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels (457 and 1054 IU/l, respectively) and increased viral DNA by HBV polymerase chain reaction (PCR). The fourth infliximab infusion was canceled, and entecavir 0.5 mg/day was prescribed. Then AST/ALT levels began to decrease and returned to normal range after 3 months. Followup HBV PCR showed negative results. CONCLUSION: We found 1 HBV reactivation case among 8 inactive HBsAg carriers following anti-TNF-alpha therapy. This finding supports the prophylactic use of antiviral agents in HBV carriers, even if they have normal liver function or an undetectable viral load | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF RHEUMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Alanine Transaminase/blood | - |
dc.subject.MESH | Antibodies, Monoclonal/adverse effects | - |
dc.subject.MESH | Antibodies, Monoclonal/immunology | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use | - |
dc.subject.MESH | Antirheumatic Agents*/adverse effects | - |
dc.subject.MESH | Antirheumatic Agents*/immunology | - |
dc.subject.MESH | Antirheumatic Agents*/therapeutic use | - |
dc.subject.MESH | Arthritis/blood | - |
dc.subject.MESH | Arthritis/drug therapy | - |
dc.subject.MESH | Arthritis/immunology | - |
dc.subject.MESH | Arthritis/virology | - |
dc.subject.MESH | Aspartate Aminotransferases/blood | - |
dc.subject.MESH | Carrier State* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B/blood | - |
dc.subject.MESH | Hepatitis B/immunology* | - |
dc.subject.MESH | Hepatitis B Surface Antigens/immunology* | - |
dc.subject.MESH | Hepatitis B virus/immunology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infliximab | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/antagonists & inhibitors* | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/immunology | - |
dc.subject.MESH | Viral Load | - |
dc.subject.MESH | Virus Activation/immunology* | - |
dc.subject.MESH | Young Adult | - |
dc.title | Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | SOO-JIN CHUNG | - |
dc.contributor.googleauthor | JA KYUNG KIM | - |
dc.contributor.googleauthor | MIN-CHAN PARK | - |
dc.contributor.googleauthor | YONG-BEOM PARK | - |
dc.contributor.googleauthor | SOO-KON LEE | - |
dc.identifier.doi | 10.3899/jrheum.081324 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00852 | - |
dc.contributor.localId | A01470 | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02889 | - |
dc.contributor.localId | A03638 | - |
dc.relation.journalcode | J01738 | - |
dc.identifier.pmid | 19797507 | - |
dc.identifier.url | http://www.jrheum.org/content/36/11/2416.long | - |
dc.contributor.alternativeName | Kim, Ja Kyung | - |
dc.contributor.alternativeName | Park, Min Chan | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.alternativeName | Lee, Soo Kon | - |
dc.contributor.alternativeName | Jeong, Su Jin | - |
dc.contributor.affiliatedAuthor | Kim, Ja Kyung | - |
dc.contributor.affiliatedAuthor | Park, Min Chan | - |
dc.contributor.affiliatedAuthor | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | Lee, Soo Kon | - |
dc.contributor.affiliatedAuthor | Jeong, Su Jin | - |
dc.citation.volume | 36 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2416 | - |
dc.citation.endPage | 2420 | - |
dc.identifier.bibliographicCitation | JOURNAL OF RHEUMATOLOGY, Vol.36(11) : 2416-2420, 2009 | - |
dc.identifier.rimsid | 51636 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.